文献速递甲状腺疾病

靶向人半乳糖凝集素-3的嵌合抗原结合片段的研制及其作为免疫正电子发射断层显像示踪剂用于甲状腺癌灵敏体内成像的验证

Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive In Vivo Imaging of Thyroid Cancer.
PubMed 文献 · Thyroid · 2020-04-30

研究开发了源自大鼠抗半乳糖凝集素-3(Gal3)单克隆抗体M3/38的嵌合人源抗原结合片段(Fab),经PAS化修饰后以89Zr标记,在两种甲状腺癌原位小鼠模型中验证其免疫PET成像效果。结果显示该示踪剂对重组Gal3抗原解离常数≤1 nM,注射后24小时在原位移植瘤中呈高选择性快速聚集,无瘤甲状腺叶未见摄取。

要点

  • αGal3-Fab-PAS200对重组Gal3抗原解离常数≤1 nM。
  • 89Zr-Dfo-PAS200-Fab在荷瘤甲状腺叶选择性聚集,注射后24小时获得强对比图像。
  • 无瘤甲状腺叶未见摄取,生物分布研究证实。

核心结论

  • 嵌合αGal3 89Zr-Dfo-PAS200-Fab示踪剂在异种移植小鼠荷瘤甲状腺叶中呈选择性聚集。
  • 该新型放射性探针有望在现有诊断程序之外改变甲状腺癌管理,并减少不必要的甲状腺切除术。

研究设计与样本

  • 从杂交瘤细胞系克隆免疫球蛋白轻链和重链可变区序列,在大肠杆菌周质中功能性生产携带人IgG1/κ恒定基因的Fab并纯化至均一。
  • 将重组Fab与由200个Pro、Ala和Ser残基组成的长无序氨基酸链融合(PAS化)以适度延长血浆半衰期并增加肿瘤摄取。
  • αGal3-Fab-PAS200与去铁胺(Dfo)偶联,在温和条件下以89Zr标记,并在甲状腺癌细胞系上测试结合。
  • 将FRO82-1或CAL62肿瘤细胞接种至无胸腺裸鼠左甲状腺叶。
  • 静脉注射约3.0 MBq的89Zr-Dfo-PAS200-Fab后,行PET/CT成像,随后定量肿瘤聚集并做免疫组化分析。

主要发现

  • αGal3-Fab-PAS200对重组Gal3抗原显示高亲和力,通过酶联免疫吸附试验、表面等离子共振光谱和放射性细胞结合试验测得的解离常数≤1 nM。
  • 89Zr(IV)标记蛋白示踪剂的体内Gal3靶向经免疫PET研究显示,在原位植入瘤中呈高度选择性且快速聚集,注射后24小时获得强对比图像。
  • 无瘤甲状腺叶未见摄取,生物分布研究亦证实。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The lack of facile methods for the specific characterization of malignant thyroid nodules makes the diagnosis of thyroid cancer (TC) challenging. Due to its restricted expression in such nodules, the cell-associated lectin galectin-3 (Gal3) has emerged as a marker for TC with growing interest for in vivo imaging as well as targeted radionuclide therapy. To accelerate translation into clinical application, we have developed a cognate chimeric human antigen-binding fragment (Fab) derived from the rat anti-Gal3 monoclonal antibody M3/38. Methods: The variable immunoglobulin (Ig) light and heavy chain sequences were cloned from the hybridoma cell line, and the corresponding Fab carrying human IgG1/κ constant genes was functionally produced in the periplasm of Escherichia coli and purified to homogeneity. To moderately prolong its plasma half-life and, thus, increase tumor uptake, the recombinant Fab was fused with a long disordered amino acid chain comprising in total 200 Pro, Ala, and Ser residues (PASylation). This novel tracer was subjected to in vitro characterization and in vivo validation by using two thyroid cancer orthotopic murine models. To this end, the αGal3-Fab-PAS200 was conjugated with deferoxamine (Dfo), labeled with 89Zr under mild conditions and tested for binding on TC cell lines. Athymic nude mice were inoculated either with FRO82-1 or with CAL62 tumor cells into the left thyroid lobe. After intravenous injection with ∼3.0 MBq of 89Zr-Dfo-PAS200-Fab, these mice were subjected to positron emission tomography (PET)/computed tomography imaging followed by quantification of tumor accumulation and immunohistochemical analysis. Results: The αGal3-Fab-PAS200 revealed high affinity toward the recombinant Gal3 antigen, with a dissociation constant ≤1 nM as measured via enzyme-linked immunosorbent assay, surface plasmon resonance spectroscopy, and radioactive cell binding assay. The in vivo Gal3-targeting by the 89Zr(IV)-labeled protein tracer, as investigated by immuno-PET, demonstrated highly selective and fast accumulation in orthotopically implanted tumors, with strong contrast images achieved 24 hours postinjection, and no uptake in the tumor-free thyroid lobe, as also confirmed by biodistribution studies. Conclusions: The chimeric αGal3 89Zr-Dfo-PAS200-Fab tracer exhibits selective accumulation in the tumor-bearing thyroid lobe of xenograft mice. Thus, this novel radioactive probe offers potential to change TC management, in addition to current diagnostic procedures, and to reduce unnecessary thyroidectomies.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Peplau E, De Rose F, Reder S, et al. Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive In Vivo Imaging of Thyroid Cancer. Thyroid. 2020. PMID: 32200708. doi:10.1089/thy.2019.0670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。